Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Change in Receivables (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Change in Receivables for 15 consecutive years, with -$72000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 146.75% to -$72000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$591000.0 through Dec 2025, down 222.11% year-over-year, with the annual reading at -$591000.0 for FY2025, 222.11% down from the prior year.
  • Change in Receivables hit -$72000.0 in Q4 2025 for Cardiff Oncology, up from -$272000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $167000.0 in Q3 2024 to a low of -$515000.0 in Q2 2023.
  • Historically, Change in Receivables has averaged -$6950.0 across 5 years, with a median of $76500.0 in 2021.
  • Biggest five-year swings in Change in Receivables: surged 2133.33% in 2021 and later crashed 595.19% in 2023.
  • Year by year, Change in Receivables stood at $141000.0 in 2021, then decreased by 14.18% to $121000.0 in 2022, then fell by 25.62% to $90000.0 in 2023, then soared by 71.11% to $154000.0 in 2024, then crashed by 146.75% to -$72000.0 in 2025.
  • Business Quant data shows Change in Receivables for CRDF at -$72000.0 in Q4 2025, -$272000.0 in Q3 2025, and $121000.0 in Q2 2025.